This trial is testing a new drug to treat people with antibody mediated rejection, which is a serious form of allograft rejection. Clazakizumab, an anti-IL6 monoclonal antibody, will be given monthly for six to twelve doses, and patients will have biopsies at 6 and 12 months to check for improvement.
The primary treatment being studied is clazakizumab, which is used to treat kidney transplant rejection. This treatment is free for patients in the trial, and there will be no placebo group.
Phase 1 & 2